#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Tag: gemcitabine
Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
#VisualAbstract: Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
Neoadjuvant chemoradiotherapy demonstrates a long-term survival benefit in pancreatic cancer patients when compared to upfront surgery
1. The use of a neoadjuvant gemcitabine-based chemoradiotherapy before surgery and adjuvant gemcitabine increased the overall survival rate when compared ...
#VisualAbstract: Gemcitabine plus cisplatin improves overall survival compared to fluorouracil plus cisplatin in metastatic or recurrent nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Camrelizumab plus gemcitabine and cisplatin improves progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...